Long-term outcome of stem cell transplantation with and without anti-tumor necrotic factor therapy in perianal fistula with Crohn’s disease

Figure 1 Closure rate with and without anti-tumor necrosis factor agents. The patients who received anti-tumor necrosis factor (TNF) treatment experienced fistula closure within 2 years and the closure rates at 1 year and 2 years were 63.0% and 66.7%, respectively. The 1-, 2-, and 3-year closure rates for the patients without anti-TNF treatment were 68.4%, 78.9%, and 81.6%, respectively. The 5-year closure rates were not significantly different according to anti-TNF agent use (66.7% vs 84.2%, P = 0.098). The anti-TNF agents used in this study were infliximab (Remicade^®, Janssen Biotech, Inc., Horsham, PA, United States) and adalimumab (Humira^®, AbbVie, Inc., North Chicago, IL, United States). TNF: Tumor necrosis factor.